Halozyme Therapeutics (NASDAQ:HALO) Rating Lowered to “Buy” at Wall Street Zen

Halozyme Therapeutics (NASDAQ:HALO) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report released on Saturday, Wall Street Zen reports.

Other equities analysts have also issued research reports about the company. Stifel Nicolaus set a $130.00 price target on Halozyme Therapeutics in a research note on Friday, October 16th. Zacks Research raised Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 13th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Citizens Jmp raised their price objective on shares of Halozyme Therapeutics from $93.00 to $149.00 and gave the stock a “market outperform” rating in a research report on Friday. Finally, Weiss Ratings raised shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, August 31st. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $106.09.

Halozyme Therapeutics Price Performance

NASDAQ HALO opened at $103.63 on Friday. The firm has a market capitalization of $11.76 billion, a P/E ratio of 26.37, a PEG ratio of 0.49 and a beta of 0.92. Halozyme Therapeutics has a 52 week low of $61.22 and a 52 week high of $134.00. The company has a 50-day moving average price of $115.19 and a 200-day moving average price of $84.73. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported $2.39 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.09. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The business had revenue of $492.97 million for the quarter, compared to the consensus estimate of $491.63 million. During the same quarter in the prior year, the business posted $1.72 EPS. The business’s revenue for the quarter was up 39.1% on a year-over-year basis. Equities research analysts anticipate that Halozyme Therapeutics will post 8.32 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 1,626 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the sale, the director owned 40,418 shares of the company’s stock, valued at $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew L. Posard sold 18,996 shares of the firm’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $107.74, for a total transaction of $2,046,629.04. Following the completion of the transaction, the director directly owned 58,839 shares in the company, valued at approximately $6,339,313.86. This represents a 24.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 125,852 shares of company stock worth $13,538,046. 2.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Mather Group LLC. increased its stake in shares of Halozyme Therapeutics by 48.9% in the 3rd quarter. Mather Group LLC. now owns 414 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 136 shares in the last quarter. North Dakota State Investment Board boosted its holdings in Halozyme Therapeutics by 4.3% in the third quarter. North Dakota State Investment Board now owns 3,598 shares of the biopharmaceutical company’s stock valued at $397,000 after acquiring an additional 147 shares during the last quarter. CoreCap Advisors LLC grew its position in Halozyme Therapeutics by 98.0% in the 3rd quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 150 shares in the last quarter. Fifth Third Wealth Advisors LLC grew its position in shares of Halozyme Therapeutics by 3.5% in the third quarter. Fifth Third Wealth Advisors LLC now owns 4,515 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 151 shares during the last quarter. Finally, Twin Capital Management Inc. raised its holdings in Halozyme Therapeutics by 1.4% in the first quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock worth $738,000 after purchasing an additional 161 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Key Stories Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Q3 revenue rose 39% year over year to $493 million and adjusted EPS of $2.39 beat estimates. Record royalty revenue increased 44% to $341 million. Halozyme also raised its 2026 revenue, royalty, EBITDA and adjusted EPS guidance. Q3 results and guidance
• Positive Sentiment: The FDA approved Johnson & Johnson’s RYBREVANT FASPRO, which uses Halozyme’s ENHANZE technology, for certain patients with advanced head and neck cancer. The expanded use could support future royalties. FDA approval
• Positive Sentiment: Halozyme said its analysis of Medicare’s drug-price negotiation rule indicates zero to minimal impact on royalty revenue through at least 2035, easing a potential long-term concern. Medicare rule assessment
• Neutral Sentiment: Citizens JMP raised its price target to $149 and maintained an outperform rating, while Wells Fargo raised its target to $110 but kept an equal-weight rating—signaling differing views on further upside. Citizens JMP rating
• Negative Sentiment: Despite the earnings beat and higher guidance, reports noted a negative share reaction and questions around the guidance reset, suggesting results may not have met elevated investor expectations. The Merck patent dispute also remains an investor focus. Earnings reaction and guidance questions

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.